Terminated PHASE3 INTERVENTIONAL NCT00075998

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)

Sponsor: InterMune

Conditions Idiopathic Pulmonary Fibrosis Lung Disease Pulmonary Fibrosis

Interventions Interferon gamma-1b (Actimmune)

Updated 5 times since 2017 Last updated: Jul 1, 2009 Started: Dec 31, 2003 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

test drug showed lack of benefit at interim analysis

Other terminated trials from InterMune

See all terminations from InterMune

Other Idiopathic Pulmonary Fibrosis trials with similar outcome

Browse all Idiopathic Pulmonary Fibrosis trials

Listed as NCT00075998, this PHASE3 trial focuses on Idiopathic Pulmonary Fibrosis and Lung Disease and remains terminated or withdrawn. Sponsored by InterMune, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InterMune

Data source: InterMune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, United States